Konrad Szymański
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Konrad Szymański has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Cezary Kowalewski
Department of Dermatology, National Medical Institute of the Ministry of the Interior and Administration, 02-507 Warsaw, Poland
2 shared publications - Katarzyna Wozniak
Department of Dermatology, National Medical Institute of the Ministry of the Interior and Administration, 02-507 Warsaw, Poland
2 shared publications - Aleksandra Juszkiewicz
Department of Internal Medicine and Rheumatology, Military Institute of Medicine—National Research Institute, 04-141 Warsaw, Poland
1 shared publication - Anna Raczkiewicz
Department of Internal Diseases and Rheumatology, Military Institute of Medicine, ul. Szaserów 128, 04-141, Warszawa, Poland
1 shared publication - Artur Bachta
Department of Internal Diseases and Rheumatology, Military Institute of Medicine, ul. Szaserów 128, 04-141, Warszawa, Poland
1 shared publication - Artur Maliborski
Department of Medical Radiology, Military Institute of Medicine, Warsaw, Poland
1 shared publication
Latest Publications
- Open Access
- 16 October 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (20) , 7318
Eight Years of Follow-Up of Rituximab in Pemphigus Vulgaris and Foliaceus at a Single Center: Assessing Efficacy and Safety in Light of Several Factors
Background/Objectives: Pemphigus vulgaris (PV) and foliaceus (PF) are autoimmune blistering diseases mediated by IgG antibodies directed against desmogleins 1 and 3 and are still considered life-threatening disorders. In recent years, rituximab has been shown to be very effective, especially in PV and mainly in short follow-ups. The role of rituximab in achieving long-lasting complete clinical remission (cCR) in pemphigus still needs to be determined. Therefore, the aim of our study was to assess the efficacy, measured by achieving long-lasting cCR, and safety of rituximab in both PV and PF over an 8-year follow-up in light of several factors (body mass index—BMI, severity of disease—PDAI, age, gender, disease duration, COVID-19 period). Methods: In total, 28 patients with pemphigus were treated with rituximab and followed-up at one center. The entire analysis was performed using statistical methods. Results: Long-lasting cCR was achieved in 5 out of 6 patients (83%) with PF and 10 of 22 (45.5%) patients with PV. Univariate and multivariate analysis disclosed that studied factors did not statistically correlated with achieving long-lasting cCR. Among studied patients, few developed side effects, mainly urinary tract infection; one patient had sepsis, and one patient died. Conclusions: This study has demonstrated that rituximab is highly effective in PF and quite effective in PV over an 8-year follow-up in relation to independently studied factors. Moreover, the COVID-19 pandemic was not a negative factor influencing cCR achievement since 82% of patients treated with rituximab during that time still achieved cCR.
- 16 October 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (20) , 7318
Open AccessEight Years of Follow-Up of Rituximab in Pemphigus Vulgaris and Foliaceus at a Single Center: Assessing Efficacy and Safety in Light of Several Factors
Background/Objectives: Pemphigus vulgaris (PV) and foliaceus (PF) are autoimmune blistering diseases mediated by IgG antibodies directed against desmogleins 1 and 3 and are still considered life-threatening disorders. In recent years, rituximab has been shown to be very effective, especially in PV and mainly in short follow-ups. The role of rituximab in achieving long-lasting complete clinical remission (cCR) in pemphigus still needs to be determined. Therefore, the aim of our study was to assess the efficacy, measured by achieving long-lasting cCR, and safety of rituximab in both PV and PF over an 8-year follow-up in light of several factors (body mass index—BMI, severity of disease—PDAI, age, gender, disease duration, COVID-19 period). Methods: In total, 28 patients with pemphigus were treated with rituximab and followed-up at one center. The entire analysis was performed using statistical methods. Results: Long-lasting cCR was achieved in 5 out of 6 patients (83%) with PF and 10 of 22 (45.5%) patients with PV. Univariate and multivariate analysis disclosed that studied factors did not statistically correlated with achieving long-lasting cCR. Among studied patients, few developed side effects, mainly urinary tract infection; one patient had sepsis, and one patient died. Conclusions: This study has demonstrated that rituximab is highly effective in PF and quite effective in PV over an 8-year follow-up in relation to independently studied factors. Moreover, the COVID-19 pandemic was not a negative factor influencing cCR achievement since 82% of patients treated with rituximab during that time still achieved cCR.
- Open Access
- 6 December 2024
- Published by MDPI AG in Dentistry Journal
- Vol. 12 (12) , 396
Direct Immunofluorescence in Oral Lichen Planus and Related Lesions: Sensitivity, Specificity, and Diagnostic Accuracy in a Single Diagnostic Center in Poland
Objectives: Our study aimed to establish the basic reliability parameters of direct immunofluorescence test results in patients with oral lichen planus. Methods: We conducted an evaluation of individual antibody classes in the DIF and ELISA (BP180 antigen), comparing these results with the classical histopathological (HP) examination in a group of patients treated within the standard healthcare in our clinic. Results: Among 66 participants with oral changes indicative of LP, only 50% received histopathological confirmation of the LP diagnosis. Among those with a DIF profile entirely typical for LP (C3+, F+), 57.1% had a positive HP result. Fibrinogen deposits were identified in 42.4% and 36.4% of individuals with positive HP results for F1 and F2, respectively; 78.8% of patients with negative HP and 57.6% with positive HP exhibited no fibrinogen deposits. Simultaneous positivity for F1 and F2 occurred in all cases where F1 was positive. HP confirmed positive DIF for C3 in 50% of cases. Fibrinogen deposits demonstrated the highest diagnostic accuracy (61%). Sensitivity and specificity for fibrinogen deposits were 36% and 42% for F1 and 79% and 82% for F2. The positive predictive values were 67% for F1 and 67% for F2, while the negative predictive values were 58% for F1 and 56% for F2. Overall diagnostic accuracy was reported at 61% for F1 and 59% for F2. Conclusions: Our data indicate the complementarity of HP and immunological test results and the necessity of using both methods together in cases of doubt.
- 6 December 2024
- Published by MDPI AG in Dentistry Journal
- Vol. 12 (12) , 396
Open AccessDirect Immunofluorescence in Oral Lichen Planus and Related Lesions: Sensitivity, Specificity, and Diagnostic Accuracy in a Single Diagnostic Center in Poland
Objectives: Our study aimed to establish the basic reliability parameters of direct immunofluorescence test results in patients with oral lichen planus. Methods: We conducted an evaluation of individual antibody classes in the DIF and ELISA (BP180 antigen), comparing these results with the classical histopathological (HP) examination in a group of patients treated within the standard healthcare in our clinic. Results: Among 66 participants with oral changes indicative of LP, only 50% received histopathological confirmation of the LP diagnosis. Among those with a DIF profile entirely typical for LP (C3+, F+), 57.1% had a positive HP result. Fibrinogen deposits were identified in 42.4% and 36.4% of individuals with positive HP results for F1 and F2, respectively; 78.8% of patients with negative HP and 57.6% with positive HP exhibited no fibrinogen deposits. Simultaneous positivity for F1 and F2 occurred in all cases where F1 was positive. HP confirmed positive DIF for C3 in 50% of cases. Fibrinogen deposits demonstrated the highest diagnostic accuracy (61%). Sensitivity and specificity for fibrinogen deposits were 36% and 42% for F1 and 79% and 82% for F2. The positive predictive values were 67% for F1 and 67% for F2, while the negative predictive values were 58% for F1 and 56% for F2. Overall diagnostic accuracy was reported at 61% for F1 and 59% for F2. Conclusions: Our data indicate the complementarity of HP and immunological test results and the necessity of using both methods together in cases of doubt.
- Open Access
- 12 July 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1214011
Case Report: Biological treatment of epidermolysis bullosa acquisita: report on four cases and literature review
Epidermolysis bullosa acquisita (EBA) is a chronic, recurrent autoimmune subepidermal bullous disease characterized by the presence of autoantibodies targeting type VII collagen -- basement membrane zone antigen. Standard therapy for EBA includes a combination of systemic corticosteroids and dapsone; however, severe cases may require advanced treatment. The current article reports on four EBA cases in which biologics: infliximab, rituximab (Rtx), and intravenous immunoglobulin (IVIG) were applied. All patients fulfilled the clinical and immunological criteria of EBA: they presented tense blisters healing with atrophic scars on the skin on traumatized areas and in mucous membranes. The diagnosis of EBA was established using numerous techniques: direct and indirect immunofluorescence, salt split skin, ELISA, Fluorescence Overlay Antigen Mapping using Laser Scanning Confocal Microscopy. Since all the patients did not achieve long-term remission on standard treatment (prednisone, dapsone) due to ineffectiveness or side effects of drugs, they eventually were treated with biologics leading to extraordinary skin improvement and stopping the disease for 1-3 years. Biologics in all patients were tolerated very well. No side effects were observed during application as well as multi-month follow-up. The presented cases provide a premise that biological drugs can be a valuable component of EBA therapy.
- 12 July 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1214011
Open AccessCase Report: Biological treatment of epidermolysis bullosa acquisita: report on four cases and literature review
Epidermolysis bullosa acquisita (EBA) is a chronic, recurrent autoimmune subepidermal bullous disease characterized by the presence of autoantibodies targeting type VII collagen -- basement membrane zone antigen. Standard therapy for EBA includes a combination of systemic corticosteroids and dapsone; however, severe cases may require advanced treatment. The current article reports on four EBA cases in which biologics: infliximab, rituximab (Rtx), and intravenous immunoglobulin (IVIG) were applied. All patients fulfilled the clinical and immunological criteria of EBA: they presented tense blisters healing with atrophic scars on the skin on traumatized areas and in mucous membranes. The diagnosis of EBA was established using numerous techniques: direct and indirect immunofluorescence, salt split skin, ELISA, Fluorescence Overlay Antigen Mapping using Laser Scanning Confocal Microscopy. Since all the patients did not achieve long-term remission on standard treatment (prednisone, dapsone) due to ineffectiveness or side effects of drugs, they eventually were treated with biologics leading to extraordinary skin improvement and stopping the disease for 1-3 years. Biologics in all patients were tolerated very well. No side effects were observed during application as well as multi-month follow-up. The presented cases provide a premise that biological drugs can be a valuable component of EBA therapy.
- Open Access
- 29 October 2018
- Published by Springer Nature in Rheumatology International
- Vol. 39 (2) , 327-336
Common atherosclerosis genetic risk factors and subclinical atherosclerosis in rheumatoid arthritis: the relevance of disease duration
Rheumatoid arthritis (RA) is a common systemic autoimmune disease characterized by increased cardiovascular morbidity. Several previous studies assessed associations between common atherosclerotic genetic risk factors and subclinical atherosclerosis (SA) in RA patients, yet most of them gave negative results. We undertook a cross-sectional study to evaluate the association between previously reported SNPs and subclinical atherosclerosis in a cohort of Polish RA patients. 29 SNPs associated with atherosclerosis in general population were genotyped in 289 RA patients: 116 patients with SA (increased carotid intima–media thickness and/or presence of carotid plaque) and 173 patients without SA. To assess the cumulative effect of SNPs we calculated 3 weighted genetic risk scores: GRSIMT, GRSCP and GRSCAD, comprising intima–media thickness-associated SNPs, carotid plaque-associated SNPs and coronary artery disease-associated SNPs, respectively. None of the SNPs showed a significant association with SA. However, we found an association between SA and GRSIMT. Interestingly, this association was limited to patients with short disease duration (P = 0.00004 vs. P > 0.5, for comparison of GRSIMT among patients within the 1st quartile of disease duration vs. others, respectively). Patients within the 1st quartile of disease duration were more frequently disease modifying anti-rheumatic drugs (DMARDs)-naïve and less frequently treated with biologics. Our study suggests that in patients with early RA subclinical atherosclerosis may be driven by similar genetic factors as in general population, while in long-lasting disease, the role common genetic risk factors may decrease. Possibly, this effect may be due to the influence of DMARDs.
- 29 October 2018
- Published by Springer Nature in Rheumatology International
- Vol. 39 (2) , 327-336
Open AccessCommon atherosclerosis genetic risk factors and subclinical atherosclerosis in rheumatoid arthritis: the relevance of disease duration
Rheumatoid arthritis (RA) is a common systemic autoimmune disease characterized by increased cardiovascular morbidity. Several previous studies assessed associations between common atherosclerotic genetic risk factors and subclinical atherosclerosis (SA) in RA patients, yet most of them gave negative results. We undertook a cross-sectional study to evaluate the association between previously reported SNPs and subclinical atherosclerosis in a cohort of Polish RA patients. 29 SNPs associated with atherosclerosis in general population were genotyped in 289 RA patients: 116 patients with SA (increased carotid intima–media thickness and/or presence of carotid plaque) and 173 patients without SA. To assess the cumulative effect of SNPs we calculated 3 weighted genetic risk scores: GRSIMT, GRSCP and GRSCAD, comprising intima–media thickness-associated SNPs, carotid plaque-associated SNPs and coronary artery disease-associated SNPs, respectively. None of the SNPs showed a significant association with SA. However, we found an association between SA and GRSIMT. Interestingly, this association was limited to patients with short disease duration (P = 0.00004 vs. P > 0.5, for comparison of GRSIMT among patients within the 1st quartile of disease duration vs. others, respectively). Patients within the 1st quartile of disease duration were more frequently disease modifying anti-rheumatic drugs (DMARDs)-naïve and less frequently treated with biologics. Our study suggests that in patients with early RA subclinical atherosclerosis may be driven by similar genetic factors as in general population, while in long-lasting disease, the role common genetic risk factors may decrease. Possibly, this effect may be due to the influence of DMARDs.